What is Predicta Biosciences?
Predicta Biosciences operates at the intersection of single-cell genomics and liquid biopsy, providing a sophisticated technological framework for the detection and characterization of complex blood-based cancers. The company's flagship GenoPredicta suite represents a paradigm shift in clinical diagnostics, enabling clinicians to derive whole-genome insights from minimal blood or bone marrow samples. By facilitating real-time monitoring of disease evolution and therapeutic response, Predicta Biosciences addresses a critical gap in precision oncology, moving beyond traditional, invasive biopsy methods to offer a more comprehensive, patient-centric approach to cancer management.
How much funding has Predicta Biosciences raised?
Predicta Biosciences has raised a total of $28.6M across 2 funding rounds:
Angel/Seed
$5.2M
Series A
$23.4M
Angel/Seed (2024): $5.2M with participation from Illumina Ventures
Series A (2025): $23.4M led by Mass General Brigham, Engine Ventures, Illumina Ventures, and Lightchain Capital
Key Investors in Predicta Biosciences
Mass General Brigham
A leading integrated healthcare system and academic medical center affiliate of Harvard Medical School, focused on translating scientific discovery into clinical practice.
Engine Ventures
A venture firm specializing in Tough Tech, providing operational expertise and capital to founders solving complex problems through breakthrough scientific innovation.
Illumina Ventures
A specialized investment firm focused on the genomics and precision health ecosystem, dedicated to accelerating innovation in life sciences and biopharmaceutical development.
What's next for Predicta Biosciences?
With the successful closure of this major enterprise-level funding, Predicta Biosciences is poised to scale its operational capabilities and expand its clinical validation studies. The strategic focus will likely shift toward enhancing the scalability of the GenoPredicta platform and fostering deeper integration within academic medical centers and oncology networks. As the company transitions from a research-heavy development phase to a more robust commercialization strategy, the focus will remain on securing regulatory milestones and expanding its footprint in the precision health market. This capital provides the necessary runway to refine its diagnostic algorithms and solidify its position as a leader in the next generation of molecular diagnostics.
See full Predicta Biosciences company page
